Zentalis Pharmaceuticals, INC. 8-K Filing

Ticker: ZNTL · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1725160

Sentiment: neutral

Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-06-03 07:00:53

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Beginning on June 3, 2024, spokespersons of Zentalis Pharmaceuticals, Inc. (the "Company") plan to present the information in the Corporate Presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference at conferences and in meetings with investors and analysts. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following Exhibit 99.1 relating to Item 7.01 shall be deemed to be furnished, and not filed: ExhibitNo. Description 99.1 Corporate Presentation, dated June 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: June 3, 2024 By: /s/ Kimberly Blackwell, M.D. Kimberly Blackwell, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing